Invasive cervical cancer following treatment of pre-invasive lesions: A potential theory based on a small case series.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 22 05 2021
revised: 23 06 2021
accepted: 30 06 2021
pubmed: 18 7 2021
medline: 22 9 2021
entrez: 17 7 2021
Statut: ppublish

Résumé

The aim of this study is to present a single department's experience on cervical cancer cases following previous excision of cervical intraepithelial neoplasia (CIN) and to discuss potential pathogenesis. Nine cervical cancer cases meeting the inclusion criteria, with available pathological and follow-up data, were considered eligible for this study. The majority (7/9) have had clear excisional margins. The interval between initial treatment and cancer diagnosis ranged from 7 to 17 years. In all cases cancer diagnosis was "unexpected", as the prior cytological and/or colposcopic evaluation was not suggestive of significant cervical pathology. All cancers were squamous, and 5/9 at stage I. The long interval between initial CIN treatment and final diagnosis as well as the normal post-treatment follow-up may suggest a 'de novo' underlying but 'hidden' carcinogenesis process. It might be that dysplastic cells entrapped within crypts (or normal metaplastic affected by the same predisposing factors) continue undergoing their evolution, undetectable by cytology and colposcopy until they invade stroma and surfaces (endo- and/or ectocervical) approximately a decade later. Heavy cauterisation of cervical crater produced post excision might be a potential culprit of this entrapment.

Identifiants

pubmed: 34273753
pii: S0301-2115(21)00334-1
doi: 10.1016/j.ejogrb.2021.06.049
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-59

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Evangelos Paraskevaidis (E)

Department of Obstetrics and Gynaecology, University Hospital of Ioannina, Ioannina, Greece. Electronic address: eparaske@uoi.gr.

Antonios Athanasiou (A)

Institute or Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

Ilkka Kalliala (I)

Institute or Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Anna Batistatou (A)

Department of Pathology, University Hospital of Ioannina, Ioannina, Greece.

Maria Paraskevaidi (M)

Institute or Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK.

Evripidis Bilirakis (E)

Department of Obstetrics & Gynaecology, IASO Hospital, Athens, Greece.

Maria Nasioutziki (M)

Second Department of Obstetrics & Gynaecology, University Hospital of Thessaloniki, Thessaloniki, Greece.

Minas Paschopoulos (M)

Department of Obstetrics and Gynaecology, University Hospital of Ioannina, Ioannina, Greece.

Deirdre Lyons (D)

Department of Obstetrics and Gynaecology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.

Marc Arbyn (M)

Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium.

Margaret Cruickshank (M)

Department of Obstetrics & Gynaecology, University of Aberdeen, Aberdeen, Scotland, United Kingdom.

Pierre Martin-Hirsch (P)

Department of Obstetrics and Gynaecology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.

Maria Kyrgiou (M)

Institute or Reproductive and Developmental Biology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH